Author

J.-B. Alberge

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 4

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 4 Approach:statistical model· 4 Research Focus:chromatin & epigenetic regulation· 2 Assay:DNA methylation· 2 Assay:ATAC-seq· 1 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Assay:ChIP-seq· 1

Frequent Co-Authors

C. Guerin-Charbonnel· 2 shared D. Heilpern-Mallory· 2 shared F. Magrangeas· 2 shared G. Getz· 2 shared I. M. Ghobrial· 2 shared L. Campion· 2 shared P. Moreau· 2 shared R. Sklavenitis-Pistofidis· 2 shared

Activity by Year

2019-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

C. Guerin-Charbonnel

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Systematic characterization of therapeutic vulnerabilities in Multiple Myeloma with Amp1q reveals increased sensitivity to the combination of MCL1 and PI3K inhibitors

R. Sklavenitis-Pistofidis, E. D. Lightbody, M. Reidy, J. Tsuji, M. P. Aranha, D. Heilpern-Mallory, D. Huynh, S. J. F. Chong, L. Hackett, N. J. Haradhvala, T. Wu, N. K. Su, B. Berrios, J.-B. Alberge, A. Dutta, , S. Manier

bioRxiv · Aug 1, 2023 · PreprintCancer Biology

Novel mechanism of MYC deregulation in Multiple Myeloma

M. Rahmat, K. Clement, J.-B. Alberge, R. Sklavenitis-Pistofidis, R. Kodgule, C. Fulco, D. Heilpern-Mallory, K. Nilsson, D. Dorfman, J. Engreitz, G. Getz, L. Pinello, R. Ryan, I. M. Ghobrial

The paper identifies a new epigenetic mechanism of MYC deregulation in multiple myeloma through enhancer accessibility and transcription factor binding, independent of translocations or amplifications.

bioRxiv · May 19, 2023 · PreprintCancer Biology

Chromatin accessibility combined with enhancer clusters activation mediates heterogeneous response to dexamethasone in myeloma cells

V. GABORIT, J. CRUARD, C. Guerin-Charbonnel, J. Derrien, J.-B. Alberge, E. Douillard, N. Roi, M. Devic, L. Campion, F. Westermann, P. Moreau, C. Herrmann, J. Bourdon, F. Magrangeas, S. Minvielle

The paper investigates how chromatin accessibility and enhancer clusters mediate heterogeneous responses to dexamethasone in myeloma cells, showing epigenomic changes linked to transcriptional heterogeneity.

bioRxiv · Sep 6, 2021 · PreprintCancer Biology

DNA hydroxymethylation reveals transcription regulation networks and prognostic signatures in multiple myeloma

J.-B. Alberge, F. Magrangeas, M. Wagner, S. Denie, C. Guerin-Charbonnel, L. Campion, M. Attal, H. Avet-Loiseau, T. Carell, P. Moreau, S. Minvielle, A. A. Serandour

This study analyzes DNA hydroxymethylation in multiple myeloma to identify regulation networks and prognostic signatures associated with disease progression and survival.

bioRxiv · Oct 16, 2019Cancer Biology

J.-B. Alberge · henhao